STAT

Opinion: The biotech industry needs to pay more attention to women’s health

The biotech industry must take note at how slowly progress has been made in women's health to date and help pave the way for increased innovation.
The birth control pill has long been seen as a "good enough" contraceptive option. But many women are eager to find longer-acting and more convenient options. Source: APStock

Even as new forms of contraception, fertility treatments, and therapies for vaginal health are emerging, there is a dearth of investment in women’s health. Despite a slew of initial public offerings and new players, including Agile, Daré, Juniper, Myovant, and ObsEva over the past few years, women’s biotech isn’t yet on everyone’s radar.

Per capita spending on women’s health was 24 percent more than spending on men’s health in 2015. Yet investment in women’s health startups is measured in millions of dollars, not billions, and  or so of venture capital investment goes to women-led companies.

You're reading a preview, sign up to read more.

More from STAT

STAT6 min readWellness
Opinion: Ebola Vaccine For Pregnant Women: One Step Closer But Still More To Go
Protecting fetuses from harmful exposures is a laudable goal. But pregnancy shouldn't automatically exclude women from receiving lifesaving therapies like the #Ebola vaccine.
STAT2 min readPolitics
Amgen, Merck, And Eli Lilly Sue Over Trump Administration Policy To Require Drug Prices In TV Ads
Amgen, Merck, Eli Lilly, and the Association of National Advertisers sued the Trump administration over a new policy to require drug prices in TV ads.
STAT4 min readSociety
Opinion: Cost-cutting Jeopardizes Many Americans’ Access To Lifesaving Oxygen Therapy
We wouldn't tolerate a pharmacy failing to provide prescribed medication. We shouldn't tolerate companies failing to deliver prescribed oxygen therapy, though it happens all the time.